Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.

ABSTRACT: Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2) inhibitor therapies improve blood glucose control and also reduce cardiovascular events and heart failure hospitalisations in patients with type 2 diabetes. Intriguingly, such clinical benefits have also been seen in patients with heart failure in the absence of type 2 diabetes although the underlying mechanisms are not clearly understood. Potential pathways include improved glycaemic control, diuresis, weight reduction and reduction in blood pressure, but none fully explain the observed improvements in clinical outcomes. More recently, novel mechanisms have been proposed to explain these be

SUBMITTER: Joshi SS 

PROVIDER: S-EPMC8223636 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature